In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (BIIB 1.37%) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (GILD -0.57%) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (CELG) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (AMGN 0.07%) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
Wall Street Backs the Wrong Biotech
By Dave Williamson
-
Apr 12, 2013 at 10:29PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NASDAQ: CELG
Celgene Corporation

Are these Wall Street upgrades really deserved?
Stocks Mentioned

Celgene Corporation
CELG

Biogen Inc.
BIIB
$205.13
(1.37%)
$2.77

Gilead Sciences, Inc.
GILD
$64.64
(-0.57%)
$0.37

Amgen Inc.
AMGN
$253.19
(0.07%)
$0.18
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable

Here's Why Editas Medicine Jumped 45.3% in November

Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better

Better Buy: Biogen vs. Celgene

Better Buy: Geron vs. Celgene
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.